JW Holdings acquires world’s first Japanese approval for early pancreatic cancer testing technology
JW Holdings was certified in novelty for its early pancreatic cancer diagnostic technology from the Japan Patent Office.
JW Holdings(CEO Sung-Kwon Han) announced on the 7th that the company has acquired Japanese approval of its original technology for the world’s first ‘multi-biomarker/test kits...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.